Clinical trials: Ovarian Carcinoma, open to volunteers
Platinum-Resistant Primary Peritoneal Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer
This is a phase-3, open-label, multicenter, two-arm treatment study to evaluate the efficacy and safety of weekly Paclitaxel Lipid Suspension compared with weekly conventional paclitaxel in participants with…
- Conditions
- Platinum-Resistant Primary Peritoneal Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer, Platinum Resistant High Grade Serous Ovarian Cancer
- Trial name
- NCT06867562
- Testing
- Paclitaxel Lipid Suspension, Conventional paclitaxel or Taxol
- Volunteers
- 166 people
- Sponsor
- Jina Pharmaceuticals Inc.
Ovarian Cancer
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2 of the study.
- Trial name
- MIROC-1 (NCT03854110)
- Testing
- misetionamide (also known as GP-2250)
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Persevere Therapeutics Inc.
Ovarian Neoplasms
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) alone or in combination with bevacizumab works in treating ovarian cancer compared to bevacizumab alone or active observation (AO).
- Trial name
- NCT07694427
- Testing
- Mocertatug rezetecan, Bevacizumab
- Where
- 12 sites in Argentina, Australia and 3 more
- Volunteers
- 720 people
- Sponsor
- GlaxoSmithKline
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
BRCA1 Gene Mutation, BRCA2 Gene Mutation
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation
- Trial name
- TUBA-WISP-II (NCT04294927)
- Testing
- Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy
- Where
- 66 sites in United States, Australia and 14 more
- Volunteers
- 3,000 people
- Sponsor
- University Medical Center Nijmegen
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253.
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07807956
- Testing
- ABBV-253
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Ovarian Cancer, Ovarian Tumor
AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery
The goal of this observational study is to learn if a computer program can tell what type of ovarian tumour a person has from a CT scan taken before surgery. The program uses artificial intelligence (AI).
- Conditions
- Ovarian Cancer, Ovarian Tumor, Borderline Ovarian Tumor
- Trial name
- OvaClass (NCT07883551)
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 1,300 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Ovarian Cancer, Ovarian Carcinoma
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer…
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovarian Cancer Stage IV, Ovarian Cancer Stage III
- Trial name
- NCT04997096
- Testing
- Exercise, Attention Control
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Solid Cancer, Metastatic Solid Tumor
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
- Conditions
- Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
- Trial name
- NCT06666270
- Testing
- SYN818
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
BRCA Hereditary Ovarian Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Uterine Lavage to Detect Ovarian Cancer Risk
This clinical trial develops a non-surgical approach using uterine lavage samples to screen for progression to ovarian cancer in high-risk patients carrying BRCA mutations.
- Conditions
- BRCA Hereditary Ovarian Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
- Trial name
- NCT07772869
- Testing
- Uterine Lavage, Archive Sample, Survey Administration
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Washington
Gynaecological Cancers, Ovarian Cancer
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
The goal of the MYSSELF (Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers) study is to investigate which biological markers (i.e., (epi)genetic biomarkers) found in…
- Conditions
- Gynaecological Cancers, Ovarian Cancer, Endometrial Cancer, Vulvar Cancer
- Trial name
- MYSSELF (NCT07902375)
- Testing
- Colli-Pee 20 mL device with UCM, Evalyn Brush
- Where
- Belgium
- Volunteers
- 730 people
- Sponsor
- Universiteit Antwerpen
Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma…
- Conditions
- Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV
- Trial name
- NCT05737303
- Testing
- nab-paclitaxel combined with carboplatin
- Where
- 11 sites in China
- Volunteers
- 538 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Mesothelioma, Neoplasms
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs.
- Conditions
- Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT06885697
- Testing
- cyclophosphamide, fludarabine, TNhYP218 CAR T Cells
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
NeoAdjuvant ChemoTherapy With KELIM Guided Interval vs. Delayed Interval Debulking Surgery
A prospective, international, multi-center, interventional trial of advanced epithelial ovarian cancer patients offered three cycles of neoadjuvant chemotherapy (NACT) and triaged with KELIM score.
- Trial name
- NACT-KELIM ID (NCT07382479)
- Testing
- 3 cycles of NACT with unfavorable KELIM score will receive 3 more cycles of NACT followed by DIDS, 3 cycles of NACT with favorable KELIM score will undergo IDS followed by 3 cycles of NACT
- Volunteers
- 485 people
- Sponsor
- Aristotle University Of Thessaloniki
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Germ Cell Ovarian Cancer, Germ Cell Tumor
SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours
The goal of this observational case-control study is to learn about the circulating and tissue microRNA expression, imaging and radiomic profiles of malignant ovarian germ cell tumours (MOGCT) compared to patients with a benign…
- Conditions
- Germ Cell Ovarian Cancer, Germ Cell Tumor, Germ Cell Cancer, Germ Cell Neoplasia
- Trial name
- SUMMER (NCT06329323)
- Testing
- Blood test, Pathology specimen miRNA expression
- Volunteers
- 24 people
- Sponsor
- Imperial College London
Ovarian Carcinoma, Cervical Carcinoma
Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.
Multicenter ambispective observational study (prospective/retrospective)
- Conditions
- Ovarian Carcinoma, Cervical Carcinoma, Endometrial Carcinoma, Vulvar Carcinoma
- Trial name
- NCT07267780
- Where
- 2 sites in Italy
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute, Naples
Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or…
- Conditions
- Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer
- Trial name
- NCT06547840
- Testing
- MOv18 IgE
- Where
- 7 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Epsilogen Ltd
Ovarian Cancer
Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
To develop a shared decision-making (SDM) tool to help Spanish-speaking patients make decisions about their maintenance therapy
- Trial name
- NCT06036810
- Testing
- Shared Medical Decision Tool, Engaging Patients in Decision Making, Literacy Spanish Language
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center